~Hepatitis C, Part 8 - References

REFERENCES

1. NIH-CSHC. NIH Consensus Statement on Management of Hepatitis C. NIH Consens State Sci Statements. 2002;19(3):1-46.
2. Wang B, Schreiber GB et al. Prevalence of transfusion-transmissible viral infections in first-time US blood donors by donation site. Transfusion. 2003;43(6):705-12.
3. Alter MJ, Mast EE et al. Hepatitis C. Infect Dis Clin North Am. 1998;12(1):13-26.
4. Garfein RS, Doherty MC et al. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18 (Suppl 1):11-9.
5. Villano SA, Vlahov D et al. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol. 1997;35(12):3274-7.
6. Alter MJ. Transmission of hepatitis C virus—route, dose, and titer. N Engl J Med. 1994;330(11):784-6.
7. Di Nardo V, Bonaventura ME et al. Low risk of HCV infection in health care workers. Infection. 1994;22(2):115.
8. Alter MJ, Coleman PJ et al. Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis. JAMA. 1989;262(9):1201-5.
9. Garfein RS, Vlahov D et al. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health. 1996;86(5):655-61.
10. Eyster ME, Alter HJ et al. Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Ann Intern Med. 1991;115(10):764-8.
11. Alter MJ. Hepatitis C virus infection in the United States. J Hepatol. 1999;31 )Suppl 1):88-91.
12. Thomas DL, Cannon RO et al. Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases. J Infect Dis. 1994;169(5):990-5.
13. Bonacini M, Puoti M. Hepatitis C in patients with human immunodeficiency virus infection: diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues. Arch Intern Med. 2000;160(22):3365-73.
14. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis. 2000;20(1):17-35.
15. Alter MJ, Margolis HS et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med. 1992;327(27):1899-905.
16. Beers M. Merck Manual of Diagnosis and Therapy, Seventeenth Edition, Centennial Edition. Whitehouse Station, NJ: Merck & Co.; 1999.
17. Hill AV, Allsopp CE et al. Common west African HLA antigens are associated with protection from severe malaria. Nature. 1991;352(6336):595-600.
18. Todd JR, West BC et al. Human leukocyte antigen and leprosy: study in northern Louisiana and review. Rev Infect Dis. 1990;12(1):63-74.
19. Alter MJ. Community acquired viral hepatitis B and C in the United States. Gut. 1993;34(2 Suppl):17-9.
20. Seeff LB, Buskell-Bales Z et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med. 1992;327(27):1906-11.
21. Alberti A, Chemello L et al. Natural history of hepatitis C. J Hepatol. 1999;31(Suppl 1):17-24.
22. Tong MJ, el-Farra NS et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995;332(22):1463-6.
23. Di Bisceglie AM. Natural history of hepatitis C: its impact on clinical management. Hepatology. 2000;31(4):1014-8.
24. Alter MJ. Epidemiology of hepatitis C. Hepatology. 1997;26(3 Suppl 1):62S-5S.
25. Advani AS, Atkeson B et al. Barriers to the participation of African-American patients with cancer in clinical trials: a pilot study. Cancer. 2003;97(6):1499-506.
26. Bonacini M, Groshen MD et al. Chronic hepatitis C in ethnic minority patients evaluated in Los Angeles County. Am J Gastroenterol. 2001;96(8):2438-41.
27. Seeff LB, Miller RN et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med. 2000;132(2):105-11.
28. Henderson SO, Bretsky P et al. Treatment of hypertension in African Americans and Latinos: the effect of JNC VI on urban prescribing practices. J Clin Hypertens (Greenwich). 2003;5(2):107-12.
29. Layden-Almer JE, Ribeiro RM et al. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology. 2003;37(6):1343-50.
30. Wiley TE, Brown J et al. Hepatitis C infection in African Americans: its natural history and histological progression. Am J Gastroenterol. 2002;97(3):700-6.
31. Mallat DB, Jeffers L. The natural history of HCV infection in African Americans. Am J Gastroenterol. 2002;97(3):520-2.
32. Ford ES. Prevalence of the metabolic syndrome in US populations. Endocrinol Metab Clin North Am. 2004;33(2):333-50.
33. Clark JM, Brancati FL et al. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98(5):960-7.
34. Kumar KS, Malet PF. Nonalcoholic steatohepatitis. Mayo Clin Proc. 2000;75(7):733-9.
35. Sugimoto K, Stadanlick J et al. Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology. 2003;37(3):590-9.
36. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol. 2002;35(5 Suppl 2):72-8.
37. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology. 2002;36(5 Suppl 1):74-83.
38. Caldwell SH, Jeffers LJ et al. Antibody to hepatitis C is common among patients with alcoholic liver disease with and without risk factors. Am J Gastroenterol. 1991;86(9):1219-23.
39. Cromie SL, Jenkins PJ et al. Chronic hepatitis C: effect of alcohol on hepatitic activity and viral titre. J Hepatol. 1996;25(6):821-6.
40. Noda K, Yoshihara H et al. Progression of type C chronic hepatitis to liver cirrhosis and hepatocellular carcinoma--its relationship to alcohol drinking and the age of transfusion. Alcohol Clin Exp Res. 1996;20(1 Suppl):95A-100A.
41. Takase S, Takada N et al. Different types of chronic hepatitis in alcoholic patients: does chronic hepatitis induced by alcohol exist? Hepatology. 1991;13(5):876-81.
42. Nalpas BF. Alcohol, hepatotropic viruses, and hepatocellular carcinoma editorial. Alcohol Clin Exp Res. 1995;19(5):1089-95.
43. Mendenhall CL, Seeff L et al. Antibodies to hepatitis B virus and hepatitis C virus in alcoholic hepatitis and cirrhosis: their prevalence and clinical relevance. The VA Cooperative Study Group (No. 119). Hepatology. 1991;14(4 Pt 1):581-9.
44. Rosman AS, Waraich A et al. Alcoholism is associated with hepatitis C but not hepatitis B in an urban population. Am J Gastroenterol. 1996;91(3):498-505.
45. Miyakawa H, Sato C et al. Hepatitis C virus infection in alcoholic liver cirrhosis in Japan: its contribution to the development of hepatocellular carcinoma. Alcohol Alcohol Suppl. 1993;1A:85-90.
46. Izumi N, Enomoto N et al. Hepatic iron contents and response to interferon-alpha in patients with chronic hepatitis C. Relationship to genotypes of hepatitis C virus. Dig Dis Sci. 1996;41(5):989-94.
47. Dieterich DT, Purow JM et al. Activity of combination therapy with interferon alfa-2b plus ribavirin in chronic hepatitis C patients co-infected with HIV. Semin Liver Dis. 1999;19(Suppl 1):87-94.
48. Benhamou Y, Bochet M et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999;30(4):1054-8.
49. Sulkowski MS, Mast EE et al. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis. 2000;30(Suppl 1):77-84.
50. Alter MJ. Non-A, Non-B hepatitis: sorting through a diagnosis of exclusion. Ann Intern Med. 1989;110(8):583-5.
51. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology. 2002;36(5 Suppl 1):21-9.
52. Iwarson S, Norkrans G et al. Hepatitis C: natural history of a unique infection. Clin Infect Dis. 1995;20(5):1361-70.
53. Puoti C, Guido M et al. Clinical management of HCV carriers with normal aminotransferase levels. Dig Liver Dis. 2003;35(5):362-9.
54. Poynard T, Ratziu V et al. Appropriateness of liver biopsy. Can J Gastroenterol. 2000;14(6):543-8.
55. Zein NN, Persing DH. Hepatitis C genotypes: current trends and future implications. Mayo Clin Proc. 1996;71(5):458-62.
56. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345(1):41-52.
57. Simmonds P, Mellor J et al. Epidemiological, clinical and therapeutic associations of hepatitis C types in western European patients. J Hepatol. 1996;24(5):517-24.
58. Kobayashi M, Tanaka E et al. The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses. Hepatology. 1996;23(4):695-9.
59. Herrmann E, Lee JH et al. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology. 2003;37(6):1351-8.
60. Neumann AU, Lam NP et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science. 1998;282(5386):103-7.
61. Neumann AU, Lam NP et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis. 2000;182(1):28-35.
62. Zeuzem S, Lee JH et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology. 1998;27(4):1149-56.
63. Gretch D, Corey L et al. Assessment of hepatitis C virus RNA levels by quantitative competitive RNA polymerase chain reaction: high-titer viremia correlates with advanced stage of disease. J Infect Dis. 1994;169(6):1219-25.
64. Liang TJ, Rehermann B et al. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 2000;132(4):296-305.
65. Farci P, Shimoda A et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science. 2000;288(5464):339-44.
66. Dufour DR, Lott JA et al. Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. Clin Chem. 2000;46(12):2027-49.
67. Dufour DR, Lott JA et al. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem. 2000;46(12):2050-68.
68. Lindsay KL. Therapy of hepatitis C: overview. Hepatology. 1997;26(3 Suppl 1):71S-7S.
69. Lindsay KL. Introduction to therapy of hepatitis C. Hepatology. 2002;36(5 Suppl 1):114-20.
70. Seeff LB, Hoofnagle JH. Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. Clin Liver Dis. 2003;7(1):261-87.
71. Farci P, Strazzera R et al. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci U S A. 2002;99(5):3081-6.
72. Nguyen TT, Sedghi-Vaziri A et al. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J Viral Hepat. 1996;3(2):75-8.
73. Pawlotsky JM. The nature of interferon-alpha resistance in hepatitis C virus infection. Curr Opin Infect Dis. 2003;16(6):587-92.
74. Pawlotsky JM. Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Res. 2003;59(1):1-11.
75. Gebo KA, Herlong HF et al. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology. 2002;36(5 Suppl 1):161-72.
76. Muir AJ, Trotter JF. A survey of current liver biopsy practice patterns. J Clin Gastroenterol. 2002;35(1):86-8.
77. Poynard T, Regimbeau C et al. Interferon for acute hepatitis C. Cochrane Database Syst Rev. 2002;(1):CD000369.
78. Jaeckel E, Manns MP. [The course and therapy of acute hepatitis C viral infection. Is a prevention of its becoming chronic possible?]. Z Gastroenterol. 2000;38(5):387-95.
79. Calabrese F, Valente M et al. Parenchymal transforming growth factor beta-1: its type II receptor and Smad signaling pathway correlate with inflammation and fibrosis in chronic liver disease of viral etiology. J Gastroenterol Hepatol. 2003;18(11):1302-8.
80. Mangia A, Santoro R et al. IL-10 haplotypes as possible predictors of spontaneous clearance of HCV infection. Cytokine. 2004;25(3):103-9.
81. Uetake TA. Interleukin 12 (IL-12) production and its relations to other cytokines in patients with chronic hepatitis C. Hepatol Res. 1999;15(3):238-51.
82. Dinarello CA. Biology of interleukin 1. Faseb J. 1988;2(2):108-15.
83. Heinrich PC, Castell JV et al. Interleukin-6 and the acute phase response. Biochem J. 1990;265(3):621-36.
84. Koziel MJ. Cytokines in viral hepatitis. Semin Liver Dis. 1999;19(2):157-69.
85. Koziel MJ, Dudley D et al. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest. 1995;96(5):2311-21.
86. Koziel MJ, Wong DK et al. Hepatitis C virus-specific cytolytic T lymphocyte and T helper cell responses in seronegative persons. J Infect Dis. 1997;176(4):859-66.
87. Koziel MJ, Walker BD. Characteristics of the intrahepatic cytotoxic T lymphocyte response in chronic hepatitis C virus infection. Springer Semin Immunopathol. 1997;19(1):69-83.
88. Jacob CO. Heritable major histocompatibility complex class II-associateddifference in the production of tumor necrosis factor-a: Relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci USA. 1987;190:1233-7.
89. Klasing KC. Nutritional aspects of leukocytic cytokines. J Nutr. 1988;118(12):1436-46.
90. McGuire W, Hill AV et al. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature. 1994;371(6497):508-10.
91. Hunnisett A, Davies S et al. Lipoperoxides as an index of free radical activity in bone marrow transplant recipients. Preliminary observations. Biol Trace Elem Res. 1995;47(1-3):125-32.
92. Calabrese F, Pontisso P et al. Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels. Hepatology. 2000;31(5):1153-9.
93. Kountouras J, Zavos C et al. Apoptosis in hepatitis C. J Viral Hepat. 2003;10(5):335-42.
94. Davis GL, Esteban-Mur R et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339(21):1493-9.
95. PEG-Intron/Rebetol™. Prescribing information.
http://www.sch-plough.com/schering_plough/pc/hepatitis.jsp
http://www.spfiles.com/pipeg-intron.pdf http://www.spfiles.com/pirebetol.pdf
96. Davis GL, Wong JB et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003;38(3):645-52.
97. Fried MW, Shiffman ML et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975-82.
98. PEG-Intron/Rebetol™. Prescribing information.
http://www.sch-plough.com/schering_plough/pc/hepatitis.jsp
http://www.spfiles.com/pipeg-intron.pdf http://www.spfiles.com/pirebetol.pdf
99. Pianko S, McHutchison JG. Treatment of hepatitis C with interferon and ribavirin. J Gastroenterol Hepatol. 2000;15(6):581-6.
100. Heathcote EJ. Treatment considerations in patients with hepatitis C and cirrhosis. J Clin Gastroenterol. 2003;37(5):395-8.
101. Ward RP, Kugelmas M et al. Management of hepatitis C: evaluating suitability for drug therapy. Am Fam Physician. 2004;69(6):1429-36.
102. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002;36(5 Suppl 1):237-44.
103. PEG-Intron/Rebetol™. Prescribing information.
http://www.sch-plough.com/schering_plough/pc/hepatitis.jsp
http://www.spfiles.com/pipeg-intron.pdf http://www.spfiles.com/pirebetol.pdf
104. PEG-Intron/Rebetol™. Prescribing information.
http://www.sch-plough.com/schering_plough/pc/hepatitis.jsp
http://www.spfiles.com/pipeg-intron.pdf
http://www.spfiles.com/pirebetol.pdf
105. Gane E. Treatment of recurrent hepatitis C. Liver Transpl. 2002;8(10 Suppl 1):28-37.
106. Bonkovsky H. Other Options for Treatment of Hepatitis C. National Institutes of Health Consensus Development Conference Panel Statement: Management of Hepatitis C. National Institutes of Health Conference on Hepatitis C, Bethesda, MD, March 24-26, 1997.
107. Yano M, Hayashi H et al. Long term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C. Am J Gastroenterol. 2002;97(1):133-7.
108. Lirussi F, Beccarello A et al. Long-term treatment of chronic hepatitis C with ursodeoxycholic acid: influence of HCV genotypes and severity of liver disease. Liver. 1999;19(5):381-8.
109. Poupon RE. Ursodeoxycholic acid for primary biliary cirrhosis: lessons from the past--issues for the future. J Hepatol. 2000;32(4):685-8.
110. Boucher E, Jouanolle H et al. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients. Hepatology. 1995;21(2):322-7.
111. Abdelmalek MF, Harrison ME et al. Treatment of chronic hepatitis C with interferon with or without ursodeoxycholic acid: a randomized prospective trial. J Clin Gastroenterol. 1998;26(2):130-4.
112. Ursodiol-PI. Ursodiol Package Insert.
113. Lechmann M, Liang TJ. Vaccine development for hepatitis C. Semin Liver Dis. 2000;20(2):211-26.
114. Conrad ME. Prevention of post-transfusion hepatitis. Lancet. 1988;2(8604):217.
115. InterMune I. INF-g—Interferon gamma1b (Actimmune™).
Http://www.Intermune.Com/. 2004.
116. Nomura HS. INF-b—Efficacy of Early Re-treatment with Interferon Beta for Relapse in Patients with genotype Ib chronic hepatitis C. Hepatol Res. 2004;28(1):36-40.
117. Nelson M. Albuferon Has Longer Half Life Than Interferon Alfa Alone and May Provide Increased Efficacy. Frontiers in Drug Development for Viral Hepatitis/HEP DART Conference, Kauai, HI, December 14–18, 2003.
118. Nelson D. IL-10—Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology. 2003;38(4):859-68.
119. Smith J. Amantadine—Amantadine Therapy for Chronic Hepatitis C. J Gen Intern Med. 2004;19:662-8.
120. Gish R. Viramidine—Safety And Efficacy Of Viramidine In Combination With Pegylated Interferon Alfa-2a For Treatment Of Hepatitis C In Therapy-Naïve Patients. Abstract 479. 39th Annual Meeting of the European Association of the Study of the Liver EASL, Berlin, Germany, 2004.
121. Iftikar R. Zadaxin (Thymalfasin)—HCV RNA and immunological responses to thymalfasin in combination with peginterferon alfa-2a in HCV non-responders: a 12-week kinetic study. Abstract 790-AASLD-53. 53rd Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, 2002.
122. Abid K. SCH 6—In vitro antiviral activity of SCH 6, a novel inhibitor of the hepatitis C virus NS3 serine protease. Abstract 137 (oral)/AASLD-54. American Association for the Study of Liver Diseases, 54th Annual Meeting, October 24-28, 2003.
123. Sjodin K, Nilsson E et al. Metabolism of N-acetyl-L-cysteine. Some structural requirements for the deacetylation and consequences for the oral bioavailability. Biochem Pharmacol. 1989;38(22):3981-5.
124. Zhou S. Merimepodib (VX-497)—The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology. 2003;310:333-42.
125. Morrissey D. Hepbzyme—Combination Of Hepbzyme™, An Anti-HBV Nuclease Resistant Ribozyme, With Lamivudine Or Interferon Improves Inhibition Of HBV Replication In Cell Culture. Abstract1101/AASLD-52. American Association for the Study of Liver Diseases, 52nd Annual Meeting, Dallas, TX, November 9-13, 2001.
126. Afdhal N. Analyses of 40 KDA peginterferon ALFA-2A (PEGASYS®) in combination with ribavirin, mycophenolate mofetil, amantadine, or amantadine plus ribavirin in patients that relapsed or did not respond to Rebetron™ therapy: a report of two randomized, multicenter, efficacy and safety studies.Abstract 277/AASLD-52. American Association for the Study of Liver Diseases, 52nd Annual Meeting, Dallas, TX, November 9-13, 2001.
127. Pockros P. Epoetin—Long-Term Treatment with Epoetin Alfa Maintains Ribavirin Dose and Hemoglobin Levels in Anemic HCV-Infected Patients Receiving Interferon/Ribavirin (IFN/RBV) Therapy. Abstract 1225 (poster). Digestive Disease Week, New Orleans, LA, 2004.
128. Levitan S. Dronabinol—Use of Dronabinol for Treatment of Common Side Effects of Chronic Hepatitis C Therapy. Abstract 1237 (poster). Digestive Disease Week, New Orleans, LA, 2004.
129. Godofsky E. NM283—Phase I/II Dose Escalation Trial Assessing Tolerance, Pharmacokinetics, and Antiviral Activity of NM283, a Novel Antiviral Treatment for Hepatitis C. Abstract 407 (plenary). Digestive Disease Week, New Orleans, LA, 2004.
130. Manns MP, McHutchison JG et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958-65.
131. Hadziyannis SJ, Papatheodoridis GV. Peginterferon-alpha2a (40 kDa) for chronic hepatitis C. Expert Opin Pharmacother. 2003;4(4):541-51.
132. PEG-Intron/Rebetol™. Prescribing information.
http://www.sch-plough.com/schering_plough/pc/hepatitis.jsp
http://www.spfiles.com/pipeg-intron.pdf http://www.spfiles.com/pirebetol.pdf
133. Reddy KR, Hoofnagle JH et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology. 1999;30(3):787-93.
134. Lau DT, Kleiner DE et al. 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology. 1998;28(4):1121-7.
135. Camma C, Giunta M et al. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol. 2001;34(4):593-602.
136. Adeyemi OM, Jensen D et al. Hepatitis C treatment eligibility in an urban population with and without HIV coinfection. AIDS Patient Care STDS. 2004;18(4):239-45.
137. Ferenci P. Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies. J Antimicrob Chemother. 2004;53(1):15-8.
138. Davis GL, Lindsay K et al. Clinical predictors of response to recombinant interferon-alpha treatment in patients with chronic non-A, non-B hepatitis (hepatitis C). The Hepatitis Interventional Therapy Group. J Viral Hepat. 1994;1(1):55-63.
139. McHutchison JG, Shad JA et al. Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy. J Viral Hepat. 2001;8(6):414-20.
140. Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis. 1995;15(1):5-14.
141. Ohkoshi S, Tawaraya H et al. A retrospective study of hepatitis C virus carriers in a local endemic town in Japan. A possible presence of asymptomatic carrier. Dig Dis Sci. 1995;40(2):465-71.
142. Moyer LA, Mast EE et al. Hepatitis C: Part I. Routine serologic testing and diagnosis. Am Fam Physician. 1999;59(1):79-88.
143. Van Thiel DH, Caraceni P et al. Chronic hepatitis C in patients with normal or near normal alanine aminotransferase levels: the role of interferon alpha 2b therapy. J Hepatol. 1995;23(5):503-8.
144. Serfaty L, Chazouilleres O et al. Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity. Gastroenterology. 1996;110(1):291-5.
145. Areias J, Velho GC et al. Lichen planus and chronic hepatitis C: exacerbation of the lichen under interferon-alpha-2a therapy. Eur J Gastroenterol Hepatol. 1996;8(8):825-8.
146. Alberti A, Chemello L et al. Treatment with interferon(s) of community-acquired chronic hepatitis and cirrhosis type C. The TVVH Study Group. J Hepatol. 1993;17(Suppl 3):123-6.
147. Brouwer JT, Hansen BE et al. Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT. J Hepatol. 1999;30(2):192-8.
148. Fattovich G, Giustina G et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol. 1997;27(1):201-5.
149. Di Bisceglie AM, Lyra AC et al. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol. 2003;98(9):2060-3.
150. Nishioka K, Watanabe J et al. A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer. 1991;67(2):429-33.
151. Nishiguchi S, Kuroki T et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995;346(8982):1051-5.
152. Grimble RF. Nutritional modulation of cytokine biology. Nutrition. 1998;14(7-8):634-40.
153. Grimble RF. Nutritional antioxidants and the modulation of inflammation: theory and practice. New Horiz. 1994;2(2):175-85.
154. Grimble RF. Effect of antioxidative vitamins on immune function with clinical applications. Int J Vitam Nutr Res. 1997;67(5):312-20.
155. Nockels CF. Protective effects of supplemental vitamin E against infection. Fed Proc. 1979;38(7):2134-8.
156. Amarakoon AM, Tappia PS et al. Endotoxin induced production of interleukin-6 is enhanced by vitamin E deficiency and reduced by black tea extract. Inflamm Res. 1995;44(7):301-5.
157. Kagan VE, Freisleben HJ et al. Generation of probucol radicals and their reduction by ascorbate and dihydrolipoic acid in human low density lipoproteins. Free Radic Res Commun. 1991;15(5):265-76.
158. Jacob RA, Kelley DS et al. Immunocompetence and oxidant defense during ascorbate depletion of healthy men. Am J Clin Nutr. 1991;54(6 Suppl):1302S-9S.
159. Peters EM, Goetzsche JM et al. Vitamin C supplementation reduces the incidence of postrace symptoms of upper-respiratory-tract infection in ultramarathon runners. Am J Clin Nutr. 1993;57(2):170-4.
160. Tappia PS, Troughton KL et al. Cigarette smoking influences cytokine production and antioxidant defences. Clin Sci (Lond). 1995;88(4):485-9.
161. Murrary RG. Harper's Biochemistry. 25 ed. Stamford, CT: Appleton & Lange;2000.
162. Sen CK, Khanna S et al. Glutathione regulation of tumor necrosis factor-alpha-induced NF-kappa B activation in skeletal muscle-derived L6 cells. Biochem Biophys Res Commun. 1997;237(3):645-9.
163. Cai J, Nelson KC et al. Oxidative damage and protection of the RPE. Prog Retin Eye Res. 2000;19(2):205-21.
164. Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. Jama. 1994;272(23):1845-50.
165. Loguercio C, Blanco FD et al. Ethanol consumption, amino acid and glutathione blood levels in patients with and without chronic liver disease. Alcohol Clin Exp Res. 1999;23(11):1780-4.
166. Verjee ZH, Behal R. Protein-calorie malnutrition: a study of red blood cell and serum enzymes during and after crisis. Clin Chim Acta. 1976;70(1):139-47.
167. Neri S, Ierna D et al. Association of alpha-interferon and acetyl cysteine in patients with chronic C hepatitis. Panminerva Med. 2000;42(3):187-92.
168. Jain SK, Pemberton PW et al. Oxidative stress in chronic hepatitis C: not just a feature of late stage disease. J Hepatol. 2002;36(6):805-11.
169. Chawla RK, Lewis FW et al. Plasma cysteine, cystine, and glutathione in cirrhosis. Gastroenterology. 1984;87(4):770-6.
170. Bounous G. Whey protein concentrate (WPC) and glutathione modulation in cancer treatment. Anticancer Res. 2000;20(6C):4785-92.
171. Bustamante J, Lodge JK et al. Alpha-lipoic acid in liver metabolism and disease. Free Radic Biol Med. 1998;24(6):1023-39.
172. Schepkin V, Kawabata T et al. 2D NMR of the metabolic antioxidant dihydrolipoic acid and its derivatives. Free Radic Res. 1996;25(3):195-205.
173. Kagan VE, Shvedova A et al. Dihydrolipoic acid—a universal antioxidant both in the membrane and in the aqueous phase. Reduction of peroxyl, ascorbyl and chromanoxyl radicals. Biochem Pharmacol. 1992;44(8):1637-49.
174. Handelman GJ, Han D et al. Alpha-lipoic acid reduction by mammalian cells to the dithiol form, and release into the culture medium. Biochem Pharmacol. 1994 May 18;47(10):1725-30.
175. Packer L, Tritschler HJ et al. Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med. 1997;22(1-2):359-78.

References, continued . . .


Free Shipping in the Continental U.S. on Orders over $50
The statements made here have not been evaluated by the FDA. The foregoing statements are based upon sound and reliable studies, and are meant for informational purposes. Consult with your medical practitioner to determine the underlying cause of your symptoms. Please always check your purchase for possible allergins and correct dosage on the bottle before use.

While we work to ensure that product information is correct, on occasion manufacturers may alter their ingredient lists. Actual product packaging and materials may contain more and/or different information than that shown on our Web site. We recommend that you do not solely rely on the information presented and that you always read labels, warnings, and directions before using or consuming a product. For additional information about a product, please contact the manufacturer. Content on this site is for reference purposes and is not intended to substitute for advice given by a physician, pharmacist, or other licensed health-care professional. You should not use this information as self-diagnosis or for treating a health problem or disease. Contact your health-care provider immediately if you suspect that you have a medical problem. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease or health condition. Life Ex Online assumes no liability for inaccuracies or misstatements about products.